TNF and rheumatoid arthritis: The proof of principle of the pathogenic role of the panoply of cytokines in RA derives from the observation that the administration of available biological therapeutics (subsumed as biological originator [bo] disease-modifying antirheumatic drugs [DMARDs]), blocking tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), the interleukin (IL)-6 receptor (IL-6R) (tocilizumab), or IL-1 (anakinra), is associated with clinical improvement [24].